| HS Code | 794759 |
| Chemical Name | beta-Propiolactone |
| Cas Number | 57-57-8 |
| Molecular Formula | C3H4O2 |
| Molecular Weight | 72.06 g/mol |
| Appearance | Colorless to slightly yellow liquid |
| Melting Point | -33.4 °C |
| Boiling Point | 162 °C (decomposes) |
| Flash Point | 75 °C (closed cup) |
| Solubility | Soluble in water, ethanol, acetone, and chloroform |
| Specific Gravity | 1.146 at 20 °C |
| Refractive Index | 1.4131 at 20 °C |
| Purity | ≥98% (veterinary grade) |
| Stability | Polymerizes upon prolonged storage or heating; requires stabilization |
| Storage Conditions | Store in airtight containers under refrigeration at 2-8°C, protected from light |
| Safety Classification | Hazardous; carcinogenic, mutagenic, toxic by inhalation, skin contact, and ingestion |
As an accredited Beta-propiolactone Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Supplied in sealed double polyethylene bags within an aluminum foil pouch, 1 kg per container, with tamper-evident closure. |
| Container Loading (20′ FCL) | 20′ FCL container loading of Beta-propiolactone Veterinary Grade API, safely packed for tablets, injections, capsules, powders, granules, premix, and solutions. |
| Shipping | Shipped in UN-approved, sealed hazardous-material containers in compliance with IATA/IMDG/ADR regulations. Requires temperature-controlled transport, protection from moisture, and clear hazard labeling. Documentation includes SDS, certificate of analysis, and handling protocols. Dedicated chemical logistics ensure safe delivery of this veterinary-grade API for pharmaceutical formulations worldwide. |
| Storage | Store Beta-propiolactone Veterinary Grade API in a tightly sealed, original container in a cool, dry, well-ventilated area at 2–8°C. Protect from light, moisture, and heat sources. Keep away from incompatible materials, including strong oxidizers, acids, and bases. Ensure secondary containment and strict access control due to its hazardous, temperature-sensitive nature. |
| Shelf Life | Shelf life: 24 months in unopened original containers, stored cool, dry, and protected from light. |
Veterinary-grade beta-propiolactone is handled as a liquid process inactivating agent rather than a retained active residue in finished tablets, capsules, granules, or premixes; the dosage-form list covering tablets, injections, capsules, powders, granules, premix, and solutions refers to downstream biological presentations whose upstream antigen or biological raw material has been treated with beta-propiolactone. The compound has a molecular weight of 72.06 g/mol, boiling point of 162 °C, and density of 1.146 g/mL at 20 °C. In clarified allantoic fluid and primary chicken embryo fibroblast harvests for Newcastle disease virus genotype VII, avian influenza virus H9N2, and infectious bronchitis virus Mass-type, beta-propiolactone is introduced after 0.45 µm filtration and before antigen pooling at a final concentration of 0.05% v/v to 0.15% v/v. Inactivation is performed in jacketed 316L stainless steel vessels fitted with pitched-blade impellers at 80–120 rpm; pH is held at 7.2–7.6 with 25 mM phosphate or HEPES, and the hold time is 18–24 h at 4–8 °C. Residual lactone is then hydrolyzed by warming to 37 °C for 2–3 h or quenched with 0.2% w/v sodium thiosulfate before antigen concentration on 100 kDa tangential-flow polyethersulfone cassettes. Compliance testing for this matrix invokes USDA 9 CFR 113.35 virucidal activity verification, sterility per Ph. Eur. 2.6.1, and mycoplasma absence per Ph. Eur. 2.6.7. Terminal product types are oil-emulsion injectable vaccines in 0.3 mL and 0.5 mL doses filled into 500 mL or 1,000 mL polypropylene bottles, plus inactivated antigen concentrates supplied as frozen liquids or lyophilized powders.
| Biological matrix | BPL final concentration | Inactivation window | Residual removal step | Terminal product class |
|---|---|---|---|---|
| Poultry allantoic fluid / CEF | 0.05%–0.15% v/v | 4–8 °C, 18–24 h | 37 °C, 2–3 h; thiosulfate | Oil-emulsion injection; lyophilized antigen powder |
| Rabies BHK-21 / Vero harvest | 0.025%–0.05% v/v | 2–8 °C, 18–24 h | 37 °C, 2 h; diafiltration | Injectable suspension |
| Bovine MDBK multivalent harvest | 0.05%–0.15% v/v | 4 °C, 20–24 h | 37 °C, 2 h; thiosulfate; UF/DF | Injectable emulsion; lyophilized powder |
| Equine MDCK viral harvest | 0.04%–0.08% v/v | 4–8 °C, 20 h | 37 °C, 2 h; thiosulfate | Injectable water-in-oil emulsion |
| Fish CHSE-214 / EPC harvest | 0.02%–0.04% v/v | 2–8 °C, 18–20 h | 37 °C, 1.5 h; thiosulfate | Intraperitoneal emulsion; lyophilized powder |
| Animal serum / porcine trypsin | 0.05%–0.1% v/v | 4 °C, 18 h | 37 °C, 2 h; adsorption | Filtered serum; lyophilized trypsin powder |
| Swine PK-15 / Vero viral harvest | 0.025%–0.1% v/v | 4–8 °C, 18–24 h | 37 °C, 1–2 h; thiosulfate; UF/DF | Injectable emulsion; lyophilized powder |
Rabies virus strains CVS-11 and SAD-B19 propagated on BHK-21 or Vero cell monolayers are harvested, clarified through 0.45 µm + 0.2 µm capsule filters, and inactivated with beta-propiolactone at 0.025% v/v to 0.05% v/v in phosphate-buffered saline at 2–8 °C for 18–24 h. The limiting variable in this stream is not the nominal BPL concentration alone but the total protein content of the clarified harvest: at protein loads above 1.2 mg/mL, alkylation competition reduces free lactone available for viral nucleic acid modification and can prolong inactivation unless a split-dose addition is used. Some dossiers therefore introduce half of the calculated volume at time zero and the remaining half at 2 h, although published data for this specific split-addition configuration in veterinary rabies dossiers is limited. After the alkylation hold, the suspension is warmed to 37 °C for 2 h to accelerate residual lactone hydrolysis, and any remaining reactive species is neutralized with sodium thiosulfate before 100 kDa tangential-flow diafiltration against 5 volumes of PBS. Aluminum hydroxide gel is then added to the purified antigen stream, and the adsorbed inactivated virion suspension is filled as an injectable vaccine. Release specifications align with WHO TRS 982 and Ph. Eur. 2.6.1; terminal product type is an injectable suspension in 1 mL Type I glass vials for companion animal use.
Bovine viral diarrhea virus types 1 and 2, bovine herpesvirus type 1, parainfluenza type 3 virus, and bovine respiratory syncytial virus are amplified in serum-free MDBK suspension cultures at 2 × 10⁶ cells/mL; harvest is initiated when cell viability falls to 60–70%, followed by depth filtration and 0.2 µm membrane clarification. Beta-propiolactone is added at 0.05% v/v to 0.15% v/v at 4 °C for 20–24 h, with process pH maintained at 7.0–7.4 using 25 mM HEPES because lower pH accelerates lactone hydrolysis but may destabilize herpesvirus envelope glycoproteins and reduce antigen yield. The inactivated multivalent antigen pool is warmed to 37 °C for 2 h, quenched with 0.1 M sodium thiosulfate at a stoichiometric excess, and exchanged by 100 kDa ultrafiltration/diafiltration against phosphate-buffered saline. Formulation may include aluminum hydroxide, oil-in-water, or carbomer adjuvants depending on the target species. Sterility, mycoplasma absence, and inactivation completeness are verified by Ph. Eur. 2.6.1, Ph. Eur. 2.6.7, and USDA 9 CFR 113.35; target animal safety data are generated under VICH GL44. Terminal product types include injectable emulsion in 10-dose vials and lyophilized powder for reconstitution with sterile diluent before subcutaneous or intramuscular administration to cattle.
When donor animal serum or porcine trypsin is incorporated into upstream veterinary cell-culture processes, beta-propiolactone is applied as a viral inactivation treatment before sterile filtration or freeze-drying. Fetal bovine serum and adult equine serum are adjusted to pH 7.2–7.6 with sodium bicarbonate, cooled to 4 °C, and treated with 0.05% v/v to 0.1% v/v BPL for 18 h; after hydrolysis at 37 °C for 2 h, residual lactone and its hydrolysis product are reduced by activated carbon adsorption and 0.1 µm filtration. Porcine trypsin solutions follow the same alkylation window but require diafiltration against 5 volumes of 1 mM hydrochloric acid after neutralization to preserve proteolytic activity. BPL alone is less effective against non-enveloped viruses such as porcine parvovirus and certain circovirus types; therefore, upstream raw-material safety strategies in whole-serum and trypsin applications typically couple BPL with orthogonal treatments such as gamma irradiation or high-temperature short-time processing when non-enveloped viral risk is identified. Compliance is verified against 21 CFR 610.15(b) for sterilizing agents and Ph. Eur. 2.6.7; terminal product types include sterile-filtered liquid serum in 500 mL bottles and lyophilized trypsin powder in 25 g containers.
In equine influenza A/H3N8 and equine herpesvirus types 1 and 4 harvests from MDCK cell culture, beta-propiolactone is introduced at 0.04% v/v to 0.08% v/v at 4–8 °C for 20 h after depth-filter clarification. Alkylation before adjuvant emulsification is preferable to post-emulsification treatment because the oil phase in final adjuvanted emulsions binds BPL and slows hydrolysis, creating a residual-lactone measurement problem in release testing. After the inactivation hold, the aqueous antigen stream is warmed to 37 °C for 2 h, and residual BPL is neutralized with sodium thiosulfate; the inactivated antigen is then concentrated by ultracentrifugation at 100,000 × g for 4 h and dialyzed against phosphate-buffered saline. The purified antigen is emulsified with mineral oil, purified saponin, or aluminum hydroxide gel to form a stable water-in-oil or oil-in-water vaccine. Sterility per Ph. Eur. 2.6.1 and inactivation completeness per USDA 9 CFR 113.35 are performed on the pre-emulsion bulk and final container. Terminal product type is an injectable emulsion in 1 mL prefilled syringes for intramuscular administration to horses.
For coldwater aquaculture viral vaccines, inactivation protocols are adjusted downward because fish cell harvests have lower total protein and because excessive BPL damages viral surface subunits used in bath and oral powder presentations. In IPNV, IHNV, and SAV3 harvests from CHSE-214 or EPC cells, beta-propiolactone is added at 0.02% v/v to 0.04% v/v at 2–8 °C for 18–20 h; pH is maintained at 7.0–7.4 with 20 mM HEPES. After hydrolysis at 37 °C for 1.5 h and neutralization with 0.1 M sodium thiosulfate, the antigen is concentrated by ultrafiltration and either emulsified for injection or lyophilized and blended into granular oral or immersion premix in hatchery-specific programs. Published data for the oral and immersion premix configurations is limited; injectable oil-adjuvanted antigen remains the most reproducible terminal presentation. Compliance testing uses Ph. Eur. 2.6.1, Ph. Eur. 2.6.7, and relevant WOAH Aquatic Manual chapters; terminal product types include intraperitoneal oil-emulsion in 250 mL collapsible bags and lyophilized powder for bath or oral premix.
Porcine circovirus type 2 capsid antigen expressed in PK-15 cells and porcine epidemic diarrhea virus propagated in Vero cells are harvested and clarified through 0.65 µm glass-fiber depth filtration followed by 0.2 µm membrane filtration. Beta-propiolactone is applied at 0.05% v/v to 0.1% v/v for PCV2 antigen and 0.025% v/v to 0.05% v/v for PEDV antigen at 4–8 °C for 18–24 h. Because PEDV is a coronavirus with a lipid envelope and PCV2 is a non-enveloped capsid antigen, the higher BPL ratio for PCV2 is used to compensate for the absence of a lipid bilayer and to achieve reproducible inactivation; if residual BPL is detected by gas chromatography after hydrolysis, the batch is re-hydrolyzed at 37 °C for an additional 1 h before neutralization. The neutralized antigen pools are diafiltered through 100 kDa cassettes and formulated with carbomer or oil-in-water adjuvants into sow and gilt vaccines. Release testing includes USDA 9 CFR 113.35 and Ph. Eur. 2.6.1. Terminal product type is an injectable emulsion in 50-dose vials; lyophilized powder presentation has been used in autogenous vaccine programs, while published data for tablets or capsules containing BPL-inactivated PCV2 or PEDV antigen is limited.
Competitive Beta-propiolactone Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Beta-propiolactone Veterinary Grade API, supplied under model BPL-VET-LQ-01, is a liquid alkylating agent intended for controlled inactivation of viral and bacterial antigens in veterinary biological manufacturing and for vapour-phase decontamination of moisture-stable components used in tablets, capsules, powders, granules, premixes, and injectable solutions. The substance is registered as CAS 57-57-8; its molecular formula is C₃H₄O₂ and its molar mass is 72.06 g/mol. At 20 °C the neat liquid density is 1.146 g/cm³, and the normal boiling point is approximately 162 °C. The product is not directly compressed into tablets or filled into capsules because the active moiety is a hydrolytically unstable liquid; instead, the product functions as a processing agent in liquid vaccine inactivation and in surface decontamination of dry dosage components.
On production-scale inactivated vaccine lines, beta-propiolactone is metered into the antigen suspension in a jacketed 316L stainless-steel reactor fitted with a pH-stat and an axial-flow impeller. The impeller tip speed is restricted to below 2.5 m/s to limit shear-induced heating, and the neat liquid is injected through a dip tube below the liquid surface using a positive-displacement pump. The jacket is held at 2–8 °C during addition, while the subsequent hydrolysis hold is performed at 20–37 °C. A local temperature excursion above 25 °C during addition shortens the aqueous half-life and reduces the effective alkylation titre before uniform distribution is achieved; therefore temperature mapping of the vessel is included in the installation qualification. The pH is maintained between 7.2 and 7.6 with 0.1 M sodium hydroxide because ring-opening hydrolysis releases acidic species that can lower broth pH below 6.5 and destabilise pH-sensitive antigens. Published data for this specific configuration is limited for many veterinary antigen matrices; each addition rate is therefore confirmed by kill-curve validation rather than by a fixed nominal percentage.
| Parameter | Release limit | Reference method |
|---|---|---|
| Appearance | Clear, colourless to pale yellow liquid | Visual inspection against a white background |
| Purity | ≥ 97.0% | Gas chromatography with flame ionisation detection; USP ⟨621⟩ |
| Water content | ≤ 0.50% | Karl Fischer titration; USP ⟨921⟩ Method Ia |
| Density at 20 °C | 1.140–1.150 g/cm³ | USP ⟨841⟩ |
| Refractive index nD20 | 1.4100–1.4200 | Ph. Eur. 2.2.6 |
| Related substances, total | ≤ 1.0% | GC-FID; USP ⟨621⟩ |
| Non-volatile residue | ≤ 0.10% | Gravimetric, 105 °C |
The liquid concentrate is packaged in nitrogen-purged borosilicate glass ampoules or fluoropolymer-lined HDPE containers. Storage is specified at 2–8 °C; freezing is not permitted. The material is moisture-sensitive, and containers are opened only inside an isolator with a dew point below −20 °C. Transfer lines are constructed of stainless steel or polytetrafluoroethylene; polycarbonate and cellulose-based seals are avoided because the cyclic ester can attack the polymer surface.
Where the product is cited for tablets, capsules, powders, granules, and premixes, the application is indirect. Beta-propiolactone vapour is generated from the liquid in a 316L stainless-steel flash evaporator maintained at 50–60 °C and injected into a sealed decontamination chamber with a dew-point sensor controlling relative humidity between 70% and 80%. The chamber is pre-conditioned at 20–25 °C. Articles are arranged on stainless-steel mesh trays to allow vapour circulation. Decontamination efficacy is challenged with biological indicators of Bacillus subtilis var. niger ATCC 9372 placed in corners, under capsule shells, and at the centre of shallow granule layers. The cycle is accepted only when all indicators are inactivated after recovery; a single positive indicator invalidates the load. Penetration into static powder beds is not considered reliable; deep-bed decontamination requires fluidisation or tumbling to expose free surfaces. Published data for this specific configuration in veterinary premix carriers is limited, so cycle-specific penetration studies are required.
For hard gelatin capsule shells and film-coated tablets, the same vapour process can be applied before filling or packaging, provided the moisture content of the shell is not altered beyond specification. Gelatin shells should be kept below their moisture equilibrium threshold; exposure to high humidity during beta-propiolactone vapour cycles can increase shell softening. Routine testing after decontamination should include moisture content by Karl Fischer titration according to USP ⟨921⟩ and shell brittleness by weight-loss on drying. The product must not be sprayed directly onto powders or granulates because liquid contact causes localised hydrolysis, agglomeration, and loss of flowability. For premix carrier materials such as lactose monohydrate, limestone, or cereal middlings, surface treatment is performed only after drying and before spray uptake of vitamins and trace minerals. Compatibility studies exclude amine-based excipients and bicarbonate buffers because rapid alkylation or acid release can compromise the premix matrix.
In inactivated veterinary viral vaccines, beta-propiolactone is selected over formaldehyde where downstream free-formaldehyde residual assays or toxoid-like protein crosslinking are process bottlenecks. Formaldehyde inactivation produces methylol adducts and Schiff bases that may persist unless neutralised with sodium bisulfite; residual formaldehyde is typically measured by Ph. Eur. 2.4.18 or an equivalent colorimetric assay. Beta-propiolactone reacts through nucleophilic ring-opening and eventually hydrolyses to beta-hydroxypropionic acid, which is not detected by the free-formaldehyde method. That difference shifts the analytical burden from residual carbonyl quantitation to residual alkylating activity and pH change. The product also differs from binary ethylenimine, which requires in situ generation from 2-bromoethylamine hydrobromide under alkaline conditions and leaves aminoalcohol residues. The comparative profile of the three inactivants is summarised below.
| Property | Beta-propiolactone | Formaldehyde | Binary ethylenimine |
|---|---|---|---|
| Reactive species | Cyclic ester | Carbonyl electrophile | Aziridine intermediate |
| Typical use stage | Liquid antigen inactivation, 2–8 °C addition | Liquid antigen inactivation, 20–37 °C | Liquid antigen inactivation, alkaline pH |
| Post-treatment residue | Beta-hydroxypropionic acid | Free formaldehyde and formic acid | Aminoalcohols and polymeric residues |
| Key analytical endpoint | Residual alkylating activity, pH, ion chromatography | Free formaldehyde; Ph. Eur. 2.4.18 | Residual binary ethylenimine; HPLC with derivatisation |
| Handling constraint | Closed handling, 2–8 °C storage, moisture exclusion | Local exhaust ventilation | In situ generation from 2-bromoethylamine hydrobromide |
| Effect on protein antigens | Nucleic acid alkylation predominates; protein modification is limited | Protein crosslinking and methylol formation | Protein alkylation possible |
For injectable solutions and liquid vaccine fluids, residual beta-propiolactone is diluted further after inactivation and subjected to a hydrolysis hold. In a validated cycle, the treated fluid is warmed to 37 °C and held for 2 h under constant agitation in a closed vessel; the pH is maintained between 7.2 and 7.6 with 0.1 M sodium hydroxide. After hydrolysis, the fluid is clarified through a 0.45 µm filter and diafiltered against not less than 5 volumes of phosphate-buffered saline using a 10 kDa tangential-flow ultrafiltration membrane. The permeate is monitored for conductivity and pH; a conductivity return to buffer baseline is used as an in-process indicator of low-molecular-mass removal. Final lots are tested for sterility by Ph. Eur. 2.6.1 and for endotoxins by Ph. Eur. 2.6.14.
Residual beta-propiolactone in aqueous process fluids is measured by gas chromatography with flame ionisation detection using a polar polyethylene glycol column. The limit of quantitation for the free lactone is 0.1 ppm; hydrolysis products require ion chromatography with suppressed conductivity detection. For solid dosage components exposed to vapour, residual solvent analysis is performed by headspace GC-MS according to USP ⟨467⟩. A release criterion of not more than 1 ppm beta-propiolactone is applied to capsules and granules intended for direct animal consumption, although published data for this specific configuration is limited and each matrix must be validated for recovery. The analytical sample preparation must be completed within 15 min of sampling to prevent hydrolytic loss before injection.
The hydrolytic degradation rate of beta-propiolactone in aqueous media is pH- and temperature-dependent. In phosphate-buffered systems at 25 °C, the degradation half-life is commonly cited in the range of 3–4 h; at 4 °C the rate is substantially slower, permitting a longer working window for addition and mixing. Hydrolysis is accelerated by phosphate buffer above pH 8.0 and by residual free amines. Formulation development therefore avoids primary amine buffers and excess bicarbonate in the inactivation vessel. The final degradation product, beta-hydroxypropionic acid, has a low toxicological concern compared with the parent lactone, but its formation lowers pH and must be compensated by controlled base addition. Lot-to-lot variation in buffering capacity of crude antigen harvests remains a recognised processing risk; pre-batch determination of buffering capacity by titration with 0.1 M hydrochloric acid is recommended before beta-propiolactone addition.
For processes where beta-propiolactone is used as a vapour-phase decontaminant for dry premix components, residual acidic species on the treated surface can alter the stability of acid-sensitive coatings or vitamins. After aeration, surface pH is checked on a 10% aqueous extract prepared from the treated material. The extract pH should be within the registered premix specification; if the extract pH falls below the lower limit, the load is rejected or subjected to additional aeration. Aeration is continued until beta-propiolactone is not detected by headspace GC-MS at a reporting limit of 0.1 ppm as free lactone. The material is then released to blending only after moisture content, surface pH, and residual lactone results meet the approved limits.
Unlike vaporised hydrogen peroxide, beta-propiolactone is not suitable for routine surface decontamination of paper-fibre or cellulose-based packaging because the hydrolysis product can generate low pH conditions at the surface. Unlike ethylene oxide, beta-propiolactone does not require a lengthy quarantine for ethylene chlorohydrin breakdown, but it does require equivalent closed-loop emission control. The liquid product should never be combined with alkali in a closed drum; the resulting exothermic hydrolysis can generate sufficient pressure to rupture an unvented container. Waste inactivation is performed by slow addition into a jacketed reactor containing 0.1 M sodium hydroxide at 5–10 °C, followed by pH neutralisation and disposal in accordance with local hazardous waste requirements.
